DANIEL RING: Open Payments
NPI 1669987012 · CABOT, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$525 in 28 payments from 13 companies in 2025. Trend: 2023 $2,219 · 2024 $2,173 · 2025 $525
Food & beverage: $525
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 6 | $94 |
| ABBVIE INC. | 4 | $90 |
| Phathom Pharmaceuticals, Inc. | 5 | $79 |
| Janssen Biotech, Inc. | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Novo Nordisk Inc | 2 | $30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Antares Pharma, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
Products named: XELJANZ, VOQUEZNA, VRAYLAR, TREMFYA, UBRELVY, JARDIANCE, XIFAXAN, XYOSTED.
Industry payments across AR — which companies pay providers there.
